Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial

Author's Avatar
Jan 10, 2022

DexCom%2C+Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2021 to be approximately $698 million, an increase of 23% over the fourth quarter of 2020. U.S. revenue is expected to be approximately $517 million, representing growth of 15% over the fourth quarter of 2020. International revenue is expected to be approximately $181 million, an increase of 54% over the fourth quarter of 2020. International growth was approximately 41% on an organic1 basis.